Surrogate endpoints in clinical trials: when is good...good enough?
作者信息
Schnuck Jamie Olapo, Chauhan Sardar Shahmir B, Sham Jonathan G
机构信息
Department of Surgery, University of Washington, Seattle, WA, USA.
Fred Hutchinson Cancer Center, Seattle, WA, USA.
出版信息
Hepatobiliary Surg Nutr. 2024 Dec 1;13(6):1062-1064. doi: 10.21037/hbsn-24-607. Epub 2024 Nov 21.
Abstract
摘要
相似文献
1
Surrogate endpoints in clinical trials: when is good...good enough?
Hepatobiliary Surg Nutr. 2024 Dec 1;13(6):1062-1064. doi: 10.21037/hbsn-24-607. Epub 2024 Nov 21.
2
Surrogacy of Recurrence-free Survival for Overall Survival as an Endpoint of Clinical Trials of Perioperative Adjuvant Therapy in Hepatobiliary-pancreatic Cancers: A Retrospective Study and Meta-analysis.
Ann Surg. 2024 Jun 1;279(6):1025-1035. doi: 10.1097/SLA.0000000000006084. Epub 2023 Aug 28.
3
Surrogate endpoints for overall survival in digestive oncology trials: which candidates? A questionnaires survey among clinicians and methodologists.
BMC Cancer. 2010 Jun 10;10:277. doi: 10.1186/1471-2407-10-277.
4
Recurrence-free survival as a putative surrogate for overall survival in phase III trials of curative-intent treatment of colorectal liver metastases: Systematic review.
World J Clin Oncol. 2017 Jun 10;8(3):266-272. doi: 10.5306/wjco.v8.i3.266.
5
Meta-analyses evaluating surrogate endpoints for overall survival in cancer randomized trials: A critical review.
Crit Rev Oncol Hematol. 2018 Mar;123:21-41. doi: 10.1016/j.critrevonc.2017.11.014. Epub 2017 Nov 23.
6
Intermediate clinical endpoints in early-stage breast cancer: an analysis of individual patient data from the Gruppo Italiano Mammella and Mammella Intergruppo trials.
EClinicalMedicine. 2024 Mar 20;70:102501. doi: 10.1016/j.eclinm.2024.102501. eCollection 2024 Apr.
7
Tumor response and progression-free survival as potential surrogate endpoints for overall survival in extensive stage small-cell lung cancer: findings on the basis of North Central Cancer Treatment Group trials.
Cancer. 2011 Mar 15;117(6):1262-71. doi: 10.1002/cncr.25526. Epub 2010 Oct 19.
8
Relapse-Free Survival as a Surrogate for Overall Survival in the Evaluation of Stage II-III Melanoma Adjuvant Therapy.
J Natl Cancer Inst. 2018 Jan 1;110(1). doi: 10.1093/jnci/djx133.
9
Surrogate endpoints for overall survival in lung cancer trials: a review.
Expert Rev Anticancer Ther. 2017 May;17(5):447-454. doi: 10.1080/14737140.2017.1316196. Epub 2017 Apr 12.
10
Major pathologic response as a prognostic surrogate in esophageal squamous cell carcinoma patients receiving neoadjuvant chemotherapy/chemoimmunotherapy: A multi-center cohort study.
Eur J Surg Oncol. 2025 Feb;51(2):109500. doi: 10.1016/j.ejso.2024.109500. Epub 2024 Nov 24.
本文引用的文献
1
Survival benefit of adjuvant chemotherapy based on molecular residual disease detection in resected colorectal liver metastases: subgroup analysis from CIRCULATE-Japan GALAXY.
Ann Oncol. 2024 Nov;35(11):1015-1025. doi: 10.1016/j.annonc.2024.08.2240. Epub 2024 Sep 16.
2
Clinical outcomes for previously treated patients with advanced biliary tract cancer: a meta-analysis.
Future Oncol. 2024 Apr;20(13):863-876. doi: 10.2217/fon-2023-0006. Epub 2024 Feb 14.
3
Surrogacy of Recurrence-free Survival for Overall Survival as an Endpoint of Clinical Trials of Perioperative Adjuvant Therapy in Hepatobiliary-pancreatic Cancers: A Retrospective Study and Meta-analysis.
Ann Surg. 2024 Jun 1;279(6):1025-1035. doi: 10.1097/SLA.0000000000006084. Epub 2023 Aug 28.
4
How we treat advanced biliary tract cancers in the second-line setting.
Clin Adv Hematol Oncol. 2023 Jan;21(1):35-42.
5
Adjuvant -Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial.
J Clin Oncol. 2023 Apr 10;41(11):2007-2019. doi: 10.1200/JCO.22.01134. Epub 2022 Dec 15.
6
Disease-free survival as a surrogate endpoint for overall survival in adjuvant trials of pancreatic cancer: a meta-analysis of 20 randomized controlled trials.
BMC Cancer. 2020 May 14;20(1):421. doi: 10.1186/s12885-020-06910-5.
7
Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer - the NEONAX trial (AIO-PAK-0313), a prospective, randomized, controlled, phase II study of the AIO pancreatic cancer group.
BMC Cancer. 2018 Dec 29;18(1):1298. doi: 10.1186/s12885-018-5183-y.
8
Factors associated with clinical trials that fail and opportunities for improving the likelihood of success: A review.
Contemp Clin Trials Commun. 2018 Aug 7;11:156-164. doi: 10.1016/j.conctc.2018.08.001. eCollection 2018 Sep.
9
Evaluation of disease-free survival as an intermediate metric of overall survival in patients with localized renal cell carcinoma: A trial-level meta-analysis.
Cancer. 2018 Mar 1;124(5):925-933. doi: 10.1002/cncr.31154. Epub 2017 Dec 19.
10
Disease-free survival is not a surrogate endpoint for overall survival in adjuvant trials of pancreatic cancer: a systematic review of randomized trials.
HPB (Oxford). 2017 Nov;19(11):944-950. doi: 10.1016/j.hpb.2017.07.005. Epub 2017 Jul 29.
Zotero 插件